|
業務類別
|
Biotechnology |
|
業務概覽
|
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or haveno effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders. |
| 公司地址
| 3940 Trust Way, Hayward, CA, USA, 94545 |
| 電話號碼
| +1 510 780-0819 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.benitec.com |
| 員工數量
| 24 |
| Ms. Megan Boston |
Chief Financial Officer, Principal Accounting Officer and Secretary |
美元 445.61K |
14/09/2026 |
| Dr. Jerel A. Banks, M.D.,PhD |
Chairman of the Board and Chief Executive Officer |
美元 661.10K |
14/09/2026 |
| Ms. Sophie Mukadam |
Chief Operating Officer |
美元 340.85K |
14/10/2025 |
|
|
| Mr. J. Kevin Buchi |
Independent Director |
14/09/2026 |
| Mr. Edward F. Smith |
Independent Director |
14/09/2026 |
| Mr. Peter Francis |
Independent Director |
14/09/2026 |
| Dr. Jerel A. Banks, M.D.,PhD |
Chairman of the Board and Chief Executive Officer |
14/09/2026 |
| Mr. Kishan Mehta |
Independent Director |
14/09/2026 |
| Mr. David Friedman |
Independent Director |
14/09/2026 |
| Dr. Sharon Mates |
Independent Director |
14/09/2026 |
|
|
|
|
